- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03707574
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
Study Overview
Status
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage III Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIA Prostate Cancer AJCC v8
- Stage IIIB Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IIIC Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8
- Advanced Melanoma
- Stage III Colorectal Cancer AJCC v8
- Stage IIIA Colorectal Cancer AJCC v8
- Stage IIIB Colorectal Cancer AJCC v8
- Stage IIIC Colorectal Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Advanced Renal Cell Carcinoma
- Advanced Malignant Neoplasm
- Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIA1 Ovarian Cancer AJCC v8
- Stage IIIA2 Ovarian Cancer AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To procure paired newly acquired tumor tissues and blood at baseline and upon progression in patients treated for advanced cancer with molecularly targeted therapies at National Cancer Institute Community Oncology Research Program (NCORP) sites.
II. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free deoxyribonucleic acid [DNA] analysis), and nucleic acids from patients in the Biorepository, which is the Biopathology Center (BPC) at Nationwide Children's Hospital (NCH), that may be used to study mechanisms of sensitivity and resistance to cancer therapies.
III. To bank, when available, optional snap-frozen tissue (for future to be determined analysis) from patients in the Biorepository, which is the Biopathology Center (BPC) at Nationwide Children's Hospital (NCH), that may be used to study mechanisms of sensitivity and resistance to cancer therapies.
IV. To assess the feasibility of obtaining paired high-quality newly acquired tumor tissues and blood from patients being treated for advanced cancer in community-based healthcare settings (NCORP sites).
SECONDARY OBJECTIVES:
I. To perform molecular profiling assays on matched malignant tumor and blood (including but not limited to whole exome and messenger ribonucleic acid [RNA] sequencing) in order to provide physicians and patients with a clinical report from a Clinical Laboratory Improvement Act (CLIA)-certified laboratory from tumor obtained at baseline and upon progression that may be used to guide further treatment planning.
II. To make available biospecimens for studies to define potential resistance biomarkers using genomic and proteomic-based assessment platforms.
III. To contribute genetic analysis data from coded specimens to Genomic Data Commons, a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data including presentation, diagnosis, staging, summary treatment, and outcome, if possible.
IV. To identify potential predictive and prognostic biomarkers beyond any genomic alteration by which treatment may be assigned.
V. To identify resistance mechanisms using genomic DNA- and RNA-based assessment platforms.
OUTLINE:
Patients undergo collection of blood and tumor prior to starting treatment and upon disease progression (second collection of blood and tumor only for patients who do not continue to progress and achieve either an objective response [OR] or stable disease [SD] after 6 months of treatment). Samples are banked and analyzed via next generation sequencing.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Manatí, Puerto Rico, 00674
- Doctors Cancer Center
-
-
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33308
- Holy Cross Hospital
-
-
Georgia
-
Savannah, Georgia, United States, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, United States, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, United States, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, United States, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, United States, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, United States, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, United States, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, United States, 96817
- Kuakini Medical Center
-
Honolulu, Hawaii, United States, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, United States, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, United States, 96813
- Island Urology
-
Lihue, Hawaii, United States, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, United States, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, United States, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, United States, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, United States, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Illinois
-
Bloomington, Illinois, United States, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, United States, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, United States, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, United States, 62918
- SIH Cancer Institute
-
Carthage, Illinois, United States, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, United States, 62801
- Centralia Oncology Clinic
-
Decatur, Illinois, United States, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, United States, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, United States, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, United States, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, United States, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, United States, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, United States, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, United States, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, United States, 61455
- Illinois CancerCare-Macomb
-
O'Fallon, Illinois, United States, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, United States, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, United States, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, United States, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, United States, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, United States, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, United States, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, United States, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, United States, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, United States, 62702
- Springfield Clinic
-
Springfield, Illinois, United States, 62781
- Springfield Memorial Hospital
-
Swansea, Illinois, United States, 62226
- Southwest Illinois Health Services LLP
-
-
Iowa
-
Cedar Rapids, Iowa, United States, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, United States, 52402
- Physicians' Clinic of Iowa PC
-
Des Moines, Iowa, United States, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, United States, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, United States, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
West Des Moines, Iowa, United States, 50266-7700
- Methodist West Hospital
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- East Jefferson General Hospital
-
New Orleans, Louisiana, United States, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, United States, 70112
- Louisiana State University Health Science Center
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01104
- Mercy Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, United States, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, United States, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, United States, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, United States, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, United States, 48723
- Caro Cancer Center
-
Chelsea, Michigan, United States, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, United States, 48118
- Chelsea Hospital
-
Clarkston, Michigan, United States, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, United States, 48346
- Newland Medical Associates-Clarkston
-
Detroit, Michigan, United States, 48236
- Henry Ford Health Saint John Hospital
-
East China Township, Michigan, United States, 48054
- Henry Ford River District Hospital
-
Flint, Michigan, United States, 48503
- Hurley Medical Center
-
Flint, Michigan, United States, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, United States, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, United States, 48503
- Cancer Hematology Centers - Flint
-
Grosse Pointe Woods, Michigan, United States, 48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods, Michigan, United States, 48236
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods, Michigan, United States, 48236
- Henry Ford Saint John Hospital - Van Elslander
-
Lansing, Michigan, United States, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, United States, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, United States, 48154
- Hope Cancer Clinic
-
Macomb, Michigan, United States, 48044
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb, Michigan, United States, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Marlette, Michigan, United States, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Pontiac, Michigan, United States, 48341
- Hope Cancer Center
-
Pontiac, Michigan, United States, 48341
- Newland Medical Associates-Pontiac
-
Pontiac, Michigan, United States, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, United States, 48341
- Michigan Healthcare Professionals Pontiac
-
Rochester Hills, Michigan, United States, 48309
- Henry Ford Rochester Hospital
-
Saginaw, Michigan, United States, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, United States, 48601
- MyMichigan Medical Center Saginaw
-
Sterling Heights, Michigan, United States, 48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City, Michigan, United States, 48764
- MyMichigan Medical Center Tawas
-
Warren, Michigan, United States, 48088
- Advanced Breast Care Center PLLC
-
Warren, Michigan, United States, 48093
- Macomb Hematology Oncology PC
-
Warren, Michigan, United States, 48093
- Henry Ford Madison Heights Hospital - Breast
-
Warren, Michigan, United States, 48093
- Henry Ford Health Warren Hospital
-
Warren, Michigan, United States, 48093
- Henry Ford Warren Hospital - GLCMS
-
West Branch, Michigan, United States, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, United States, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, United States, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Burnsville, Minnesota, United States, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, United States, 55337
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, United States, 55008
- Cambridge Medical Center
-
Coon Rapids, Minnesota, United States, 55433
- Mercy Hospital
-
Edina, Minnesota, United States, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, United States, 55432
- Unity Hospital
-
Maple Grove, Minnesota, United States, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, United States, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, United States, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, United States, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, United States, 55454
- Health Partners Inc
-
Monticello, Minnesota, United States, 55362
- Monticello Cancer Center
-
New Ulm, Minnesota, United States, 56073
- New Ulm Medical Center
-
Princeton, Minnesota, United States, 55371
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, United States, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, United States, 55101
- Regions Hospital
-
Saint Paul, Minnesota, United States, 55102
- United Hospital
-
Shakopee, Minnesota, United States, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, United States, 55082
- Lakeview Hospital
-
Waconia, Minnesota, United States, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, United States, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, United States, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, United States, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Bonne Terre, Missouri, United States, 63628
- Parkland Health Center-Bonne Terre
-
Cape Girardeau, Missouri, United States, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, United States, 63703
- Mercy Cancer Center - Cape Girardeau
-
Farmington, Missouri, United States, 63640
- Parkland Health Center - Farmington
-
Jefferson City, Missouri, United States, 65109
- MU Health Care Goldschmidt Cancer Center
-
Sainte Genevieve, Missouri, United States, 63670
- Sainte Genevieve County Memorial Hospital
-
St Louis, Missouri, United States, 63131
- Missouri Baptist Medical Center
-
Sullivan, Missouri, United States, 63080
- Missouri Baptist Sullivan Hospital
-
Sunset Hills, Missouri, United States, 63127
- BJC Outpatient Center at Sunset Hills
-
-
New York
-
New York, New York, United States, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
The Bronx, New York, United States, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, United States, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, United States, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, United States, 18017
- Lehigh Valley Hospital - Muhlenberg
-
East Stroudsburg, Pennsylvania, United States, 18301
- Pocono Medical Center
-
Hazleton, Pennsylvania, United States, 18201
- Lehigh Valley Hospital-Hazleton
-
-
Wisconsin
-
Grafton, Wisconsin, United States, 53024
- Aurora Cancer Care-Grafton
-
Milwaukee, Wisconsin, United States, 53215
- Aurora Saint Luke's Medical Center
-
New Richmond, Wisconsin, United States, 54017
- Cancer Center of Western Wisconsin
-
West Allis, Wisconsin, United States, 53227
- Aurora West Allis Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patient meets all eligibility criteria for treatment of the tumors with the agents listed and has agreed to provide tissue and blood samples for this study
- Targeted therapy maybe as a singular/monotherapy or in combination with any Food and Drug Administration (FDA)-approved chemotherapies
- Patient's primary or recurrent disease is targeted-treatment naive or will be treated with a targeted therapy listed different from any previously-received targeted therapy or combination therapy as standard of care
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. Patients with a PS of 2 may be enrolled only at the discretion of the treating physician and radiologist
- Have an advanced malignancy being treated with one of the agents listed. Advanced cancer is cancer that is unlikely to be cured or controlled with treatment. The cancer may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Treatment may be given to help shrink the tumor, slow the growth of cancer cells, or relieve symptoms. Patients may be undergoing first or subsequent lines of therapy. In the case where an agent not listed is newly approved for one of the listed tumors, patients undergoing therapy with it will be able to enroll at discretion of the principal investigator (PI). This is to avoid any lag between FDA approval of a previously investigational agent and protocol modifications/updates
Have an advanced malignancy that meets one of the following criteria:
- Patients must have tumor amenable to image guided or direct vision biopsy and be willing and able to undergo a tumor biopsy for molecular profiling. The biopsy must not be associated with a significant risk of severe or major complications or death. In particular, endoscopic, open or laparoscopic surgical procedures are not to be performed to provide research specimens. However, research specimens may be provided if the patient needs to undergo such procedures for clinical reasons
Severe or major complications are considered to be those
- Requiring therapy, minor hospitalization (more than overnight but < 48 hours [h])
- Requiring major therapy; unplanned increase in level of care, prolonged hospitalization > 48 h
- Resulting in permanent adverse sequelae
- Resulting in death
Patient will be undergoing a procedure due to medical necessity during which the tissue may be collected. The following tumors may be collected only under the conditions specified and not for the sole purpose of the clinical trial:
- Brain biopsies: ONLY if the patient has medical necessity for craniotomy for clinical care
- Mediastinal, laparoscopic, gastrointestinal, or bronchial endoscopic biopsies: ONLY to be obtained incidentally to a clinically necessary procedure
Exclusion Criteria:
- Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy
- Patients currently enrolled or planning to be co-enrolled (while participating on the 10231 study) on a therapeutically interventional clinical trial aimed to treat the current malignancy
- If the patient is on chronic anticoagulation treatment, they must be able and willing to have this treatment discontinued for the biopsy. Discontinuation procedures will be those of the treating site
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Ancillary-correlative (genetic analysis)
Patients undergo collection of blood and tumor prior to starting treatment and upon disease progression (second collection of blood and tumor only for patients who do not continue to progress and achieve either an OR or SD after 6 months of treatment).
Samples are banked and analyzed via next generation sequencing.
|
Undergo collection of blood and tissue
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Obtaining tumor tissue and blood specimens
Time Frame: Up to 2 years
|
Will obtain tumor tissue and blood specimens for biobanking and to store tissues, blood, and nucleic acids for future research, including the study of matched pre and post-treatment tumor biopsies to elucidate mechanisms of resistance.
Cases will be grouped according to histology and/or treatment.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tumor tissues storage in the Biopathology Center (BPC) at Nationwide Children's Hospital (NCH) (Biorepository)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
|
Genomic analysis
Time Frame: Up to 2 years
|
Will perform genomic studies, including a pan-cancer gene panel, and contribute molecular data to the genomic data commons.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: S. P Ivy, National Cancer Institute (NCI)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Intestinal Diseases
- Respiratory Tract Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Genital Diseases, Female
- Lung Diseases
- Endocrine Gland Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Colonic Diseases
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Prostatic Neoplasms
- Lung Neoplasms
- Colorectal Neoplasms
- Ovarian Neoplasms
- Investigative Techniques
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Specimen Handling
Other Study ID Numbers
- NCI-2018-01375 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 10231 (Other Identifier: CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anatomic Stage III Breast Cancer AJCC v8
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Chemotherapy-Induced AlopeciaUnited States
-
University of Alabama at BirminghamNational Cancer Institute (NCI)TerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterCompletedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
University of Alabama at BirminghamTerminatedBreast Cancer | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
Clinical Trials on Biospecimen Collection
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
Ohio State University Comprehensive Cancer CenterGuardant Health, Inc.CompletedColorectal CarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingCholangiocarcinoma | Malignant Digestive System NeoplasmUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingCentral Nervous System TumorUnited States
-
University of California, DavisNational Cancer Institute (NCI)RecruitingGastric Carcinoma | Lung Carcinoma | Malignant Neoplasm | Bladder Carcinoma | Liver and Intrahepatic Bile Duct CarcinomaUnited States
-
Abramson Cancer Center at Penn MedicineActive, not recruiting
-
Addario Lung Cancer Medical InstituteTerminatedNon Small Cell Lung CancerUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecruitingHIV Infection | Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Lymphoma | Multicentric Castleman Disease | Plasmablastic Lymphoma | Kaposi Sarcoma | Recurrent Lymphoma | Anal Carcinoma | Recurrent Kaposi Sarcoma | Recurrent Plasmablastic Lymphoma | Transplant-Related Kaposi SarcomaUnited States